Silexion首例患者给药,现金降至480万美元
AiX — Free Expert Advisor
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Silexion Therapeutics Corp(NASDAQ: SLXN)于2026年11月13日公布2026年第三季度业绩,披露净亏损约250万美元,截至2026年9月30日现金及现金等价物为480万美元。这家临床阶段RNA干扰开发商表示,其主打候选药物SIL204于2026年9月30日在特拉维夫苏拉斯基医疗中心(TASMC)完成全球首例患者给药,用于局部晚期胰腺癌的2/3期试验。第三季度融资通过三笔交易筹集毛收入约520万美元。
背景——为何SIL204给药现在至关重要
首例患者里程碑将SIL204从规划阶段推进到实际治疗阶段,公司将此一转变称为本季度的核心事件。Silexion在获得以色列卫生部批准后,于2026年7月29日在TASMC启用试验首个研究中心,两个月后完成首例患者给药。
该试验是一项前瞻性、随机、对照、多国、开放标签研究。它测试SIL204联合标准化疗与单纯化疗,用于新诊断、未接受过治疗、肿瘤携带已确认KRAS突变的不可切除3期局部晚期胰腺癌患者。
该人群按设计较为狭窄。患者必须未接受过治疗且KRAS确认,这既影响入组速度,也影响公司未来可能追求的标签。
SIL204采用双途径给药方案:经EUS引导直接瘤内递送至原发肿瘤,加上旨在提供全身暴露的皮下注射。研究首先进行约18例患者的安全性导入队列,然后扩展为约166例患者的随机队列。
公司表示,更多以色列肿瘤中心和德国领先学术医疗机构正在推进研究中心激活,预计将在未来数月加入。Silexion未披露按季度划分的入组目标、以色列以外各中心的激活日期,或迄今筛选患者数量。
融资背景很重要,因为临床阶段肿瘤公司依靠资产负债表为试验提供资金。Silexion的现金头寸从2025年12月31日的600万美元下降,即使本季度筹集了新资金,这表明烧钱速度超过资本形成速度。
数据——数字说明了什么
利润表显示季度与年初至今趋势分化。2026年第三季度研发费用同比下降40.9%至约130万美元,2025年第三季度为220万美元。一般及行政费用增长27.3%至约140万美元,此前为110万美元。净亏损收窄24.2%至约250万美元,此前为330万美元。
九个月期间模式反转。研发费用增长28.9%至约490万美元,此前为380万美元,公司将其归因于2/3期试验的运营扩张。一般及行政费用增长20.0%至约420万美元,此前为350万美元。净亏损扩大17.3%至约880万美元,此前为750万美元。
| 指标 | 2026年第三季度 | 2025年第三季度 | 变化 |
|---|---|---|---|
| 研发费用 | 约130万美元 | 约220万美元 | -40.9% |
| 一般及行政费用 | 约140万美元 | 约110万美元 | +27.3% |
| 净亏损 | 约250万美元 | 约330万美元 | -24.2% |
| 现金及等价物 | 480万美元 | 不适用 | 对比2025年12月31日的600万美元 |
| 股东权益 | 300万美元 | 不适用 | 对比2025年12月31日的260万美元 |
截至2026年9月30日,资产负债表总资产为680万美元,总负债为390万美元。股东权益为296.8万美元,高于2025年12月31日的260.3万美元,得益于一笔156.8万美元的关联方本票不再作为非流动负债列示。
本季度融资包括2026年8月注册公开发行毛收入约250万美元、2026年9月认股权证诱导交易约84万美元,以及按市价发行销售约190万美元。季度结束后,2026年11月10日,公司实施1比24反向拆股。报告未披露发行价、认股权证行权价或稀释百分比。
分析——对市场和行业意味着什么
Silexion处于拥挤的KRAS导向肿瘤开发商领域,其差异化在于机制而非规模。公司于2026年8月报告称,临床前工作显示,在人KRAS突变胰腺癌和非小细胞肺癌细胞系中,免疫死亡受体FAS(CD95)出现统计学显著上调,免疫检查点HLA-G出现下调。
结合2026年5月报告的MHC-I上调,公司表示这些发现支持跨三条免疫通路和四种KRAS突变(G12D、G12V、G12C和G12R)的协调免疫致敏特征。Silexion称这强化了将SIL204与抗PD-(L)1检查点抑制剂疗法联合的理由。
2026年9月,公司报告称SIL204利用天然循环脂蛋白进入癌细胞并沉默突变KRAS,无需合成转染试剂或人工载体。这支持全身给药,药代动力学、细胞摄取动力学和生物分布研究仍在进行中。
The counter-argument is timing and capital. A 166-patient randomized cohort plus an 18-patient run-in is expensive, and the company ended the quarter with $4.8 million. Without additional financing, that balance covers only a fraction of the trial the company has designed. The bear case is straightforward: dilution risk if the equity window narrows.
The bull case rests on the safety run-in reading out cleanly and German sites activating on schedule. Positioning is likely split between event-driven holders awaiting the run-in data and investors who treat the reverse split and cumulative net loss as reasons to stay away. The report gives no institutional ownership figures.
Outlook — what to watch next
Three catalysts dominate. First, additional Israeli centers and German academic institutions joining the trial, which the company said are expected in the coming months without naming sites or dates. Second, completion of the approximately 18-patient safety run-in cohort, which gates expansion into the randomized phase. Third, the ongoing pharmacokinetic and biodistribution work that underpins the systemic administration claim.
On capital, the next signal is whether the company returns to the at-the-market facility or raises again. The November 10, 2026, 1-for-24 reverse split was a listing-related action, and the report gives no post-split share count.
Readers tracking this name should watch for enrollment updates and any disclosure of cash at the next reporting date. The report names no price levels, analyst targets, or valuation metrics for SLXN, so none are offered here.
Frequently Asked Questions
What does the first patient dosed mean for Silexion stock?
It marks the shift from trial setup to active treatment, which is the point at which clinical risk becomes measurable. Silexion opened its first site at TASMC on July 29, 2026, and dosed the first patient on September 30, 2026. The trial still has to complete a roughly 18-patient safety run-in before the randomized cohort of about 166 patients begins, so the milestone is early in a multi-year sequence.
Why did Silexion's cash fall to $4.8 million despite raising money?
Cash dropped from $6.0 million at December 31, 2025, to $4.8 million at September 30, 2026, even after an August offering at roughly $2.5 million, a September warrant inducement at roughly $0.84 million, and at-the-market sales of roughly $1.9 million. The nine-month net loss of approximately $8.8 million, driven by R&D of approximately $4.9 million, consumed more than the quarter's financings brought in.
What is SIL204 and how is it administered?
SIL204 is a small interfering RNA candidate that targets mutant KRAS in solid tumors. It is given through a dual-route regimen: direct EUS-guided intratumoral delivery to the primary tumor, combined with subcutaneous injections designed to provide systemic exposure. Silexion reported in September 2026 that the compound uses naturally circulating lipoproteins to enter cancer cells, which supports the systemic route.
Bottom Line
Silexion moved SIL204 into active patient treatment, but $4.8 million in cash against a 166-patient randomized trial keeps financing risk front and center.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Trade XAUUSD on autopilot — free Expert Advisor
AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
PartnerPosition yourself for the macro moves discussed above
Start TradingSponsored
Ready to trade the markets?
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.